MCRB

Seres Therapeutics Inc. (MCRB) | Rumor.io

Seres Therapeutics

MCRB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,303

Bullish sentiment (50-day avg)50%

Price to earnings ratio11.7

Market capitalization35.4M

Earnings per share-2.42

Dividend yield (TTM)—

Revenue (annual)789K

Net income (annual)5.7M

Social

What share of all stock conversation is about MCRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% -0.01

Aug 14

MCRB (Seres Therapeutics) has experienced a significant decline, with some investors questioning whether it's a buying opportunity or a trap.
Long-term holders are uncertain whether to hold for a potential recovery or exit, while others are considering cutting losses to protect their capital.
The plunge has sparked discussions about the company's plans, with some investors wondering if they will return to working on their pipeline, specifically Ser 155.

Generated by AI

Sentiment

Of the messages about MCRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.33% +29.49	44.44% +24.44	37.31% -39.05	63.46% -0.55
Bearish	16.67% -29.49	55.56% -24.44	62.69% +39.05	36.54% +0.55

Bullish· Jul 14

The company is in a strong position, with more cash in hand and no major problems until at least February/March 2027, and has further positive data on its lead product, Ser 155.
The biotech industry is in a "golden era," with the company's stock price at an all-time low, presenting an incredible opportunity for long-term growth and a risk-to-reward ratio that is heavily in favor of the bulls.
The company's stock price is expected to rise significantly, with some analysts predicting a price of $20, and the company's strong fundamentals and potential partnerships or buyouts make it an attractive investment opportunity.

Bearish· Feb 12

The company's management has been accused of selling a FDA-approved drug instead of the company, potentially leading to significant losses for investors.
The company's management has been criticized for their handling of the business, with some calling it "terrible" and others accusing them of "greed and undermining shareholders".
The company's financial situation is precarious, with some speculating that it may be near bankruptcy due to poor management decisions, such as passing up multiple offers and extending a trial into Q3 while still seeking funding.

Generated by AI

Topics

Of the messages about MCRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	20%	88.07%
Analysts	—	0%	0%	1.87%
Technical Analysis	—	100%	80%	2.87%
Macro	—	0%	0%	5.47%
Controversies	—	0%	0%	0.92%
Earnings	—	0%	0%	0.8%

Earnings· May 9

$MCRB reported better-than-expected earnings, beating EPS loss estimates by $0.07.
The company also beat revenue estimates.
This earnings beat may positively impact the stock's performance.

Analysts· Jul 23

Analysts have raised or maintained a buy rating for Seres Therapeutics ($MCRB), with price targets ranging from $7 to $32.
Oppenheimer analyst Mark Breidenbach views the recent stock price fall as an over-reaction, citing the company's undervalued pipeline and potential commercial success.
Multiple analysts, including those from Oppenheimer, Canaccord Genuity, and Chardan Capital, have lowered price targets for Seres Therapeutics ($MCRB) due to recent setbacks or re-evaluations.

Announcements· Jul 17

The company mentions a potential partnership in the oncology space, but no further details are provided.
There is no clear indication of the announcement type, such as a merger, acquisition, or product launch.
The company's focus on oncology is highlighted, but no concrete developments or updates are mentioned.

Macro· Feb 16

Seres Therapeutics, Inc. may have a heavy dependency on suppliers for vehicle parts, including body parts from Sokon and batteries and powertrain from an unknown source.
The company's potential merger with FIII could be a significant event for the company and its stakeholders.
The focus on suppliers and potential roadblocks suggests that the company's success may be heavily reliant on its ability to manage these external relationships.

Technical Analysis· Dec 10

$MCRB has been consolidating around $0.93-$0.94, with a potential breakout above $0.95.
The RSI is being pulled down, which could be a sign of a potential next leg up for $MCRB.
A third breakthrough of VWAP in one day would be a bullish sign, and the stock has already shown signs of a cup and handle pattern.

Generated by AI

Community

Of the messages about MCRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	41.67%	54.1%	63.97%	83.68%
Newcomers	58.33%	45.9%	36.03%	16.32%

Regulars· Jul 17

$MCRB is being mentioned alongside IOVA, suggesting a potential partnership or collaboration in the oncology space.
There is speculation about a potential oncology partnership involving MCRB, with one user expressing their belief in its potential.
MCRB is being used as a reference point in a discussion about time and market trends, with one user stating "I got nothing but time."

Newcomers· Jun 5

Many newcomers are focused on the company's cash runway, which has been extended to Q1 2027 due to recent transactions and reduced facility costs.
Some are optimistic about the company's balance sheet repairs and cash management, with a positive bias on the stock.
Others are concerned about the company's reliance on partnerships or additional capital raises for operations beyond Q1 2027.

Generated by AI

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Type of Product, Route of Administration, Target Indication, Therapeutic Area, End User and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period. Market expansion

23d agoYahoo Finance

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026. A live webcast of the presentation will be accessible here and will be available for replay on the “Events and Presentations” section of Seres’ website

29d agoYahoo Finance

Also Discussed

Investors talking about MCRB also mention

#	Name	Attention
1	Evelo Biosciences Inc.EVLO	0%0
2	FNCH - Finch Therapeutics Group, Inc.	——
3	Akebia Therapeutics Inc.AKBA	0.01%+0
4	PRVB - Provention Bio, Inc.	——
5	SCPH - scPharmaceuticals Inc.	——
6	TG Therapeutics Inc.TGTX	0.01%+0
7	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
8	CDTX - Cidara Therapeutics, Inc.	——
9	ETNB - 89bio, Inc.	——
10	DAWN - Day One Biopharmaceuticals, Inc.	——

Seres Therapeutics Inc.

Healthcare
Biotechnology

Seres Therapeutics Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics that modulate the human microbiome. The company’s current portfolio centers on oral microbiome-based therapies designed to address serious diseases in areas such as gastrointestinal disorders, immune-mediated conditions, and infection prevention. Its pipeline includes investigational programs aimed at restoring healthy microbial balance and improving disease-relevant functions in the gut. Seres Therapeutics serves a specialized role in the biopharmaceutical market by advancing novel treatments for medically vulnerable patient populations, with development efforts centered on microbiome therapeutics rather than traditional small-molecule or antibody drugs. Headquartered in Cambridge, Massachusetts, Seres Therapeutics is positioned within the broader biotechnology sector as a developer of targeted live biotherapeutic products.

Website

Location

101 Cambridgepark Drive

Cambridge, MA, 02140

United States

Social

What share of all stock conversation is about MCRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% -0.01

Aug 14

MCRB (Seres Therapeutics) has experienced a significant decline, with some investors questioning whether it's a buying opportunity or a trap.
Long-term holders are uncertain whether to hold for a potential recovery or exit, while others are considering cutting losses to protect their capital.
The plunge has sparked discussions about the company's plans, with some investors wondering if they will return to working on their pipeline, specifically Ser 155.

Generated by AI

Sentiment

Of the messages about MCRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.33% +29.49	44.44% +24.44	37.31% -39.05	63.46% -0.55
Bearish	16.67% -29.49	55.56% -24.44	62.69% +39.05	36.54% +0.55

Bullish· Jul 14

The company is in a strong position, with more cash in hand and no major problems until at least February/March 2027, and has further positive data on its lead product, Ser 155.
The biotech industry is in a "golden era," with the company's stock price at an all-time low, presenting an incredible opportunity for long-term growth and a risk-to-reward ratio that is heavily in favor of the bulls.
The company's stock price is expected to rise significantly, with some analysts predicting a price of $20, and the company's strong fundamentals and potential partnerships or buyouts make it an attractive investment opportunity.

Bearish· Feb 12

The company's management has been accused of selling a FDA-approved drug instead of the company, potentially leading to significant losses for investors.
The company's management has been criticized for their handling of the business, with some calling it "terrible" and others accusing them of "greed and undermining shareholders".
The company's financial situation is precarious, with some speculating that it may be near bankruptcy due to poor management decisions, such as passing up multiple offers and extending a trial into Q3 while still seeking funding.

Generated by AI

Topics

Of the messages about MCRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	20%	88.07%
Analysts	—	0%	0%	1.87%
Technical Analysis	—	100%	80%	2.87%
Macro	—	0%	0%	5.47%
Controversies	—	0%	0%	0.92%
Earnings	—	0%	0%	0.8%

Earnings· May 9

$MCRB reported better-than-expected earnings, beating EPS loss estimates by $0.07.
The company also beat revenue estimates.
This earnings beat may positively impact the stock's performance.

Analysts· Jul 23

Analysts have raised or maintained a buy rating for Seres Therapeutics ($MCRB), with price targets ranging from $7 to $32.
Oppenheimer analyst Mark Breidenbach views the recent stock price fall as an over-reaction, citing the company's undervalued pipeline and potential commercial success.
Multiple analysts, including those from Oppenheimer, Canaccord Genuity, and Chardan Capital, have lowered price targets for Seres Therapeutics ($MCRB) due to recent setbacks or re-evaluations.

Announcements· Jul 17

The company mentions a potential partnership in the oncology space, but no further details are provided.
There is no clear indication of the announcement type, such as a merger, acquisition, or product launch.
The company's focus on oncology is highlighted, but no concrete developments or updates are mentioned.

Macro· Feb 16

Seres Therapeutics, Inc. may have a heavy dependency on suppliers for vehicle parts, including body parts from Sokon and batteries and powertrain from an unknown source.
The company's potential merger with FIII could be a significant event for the company and its stakeholders.
The focus on suppliers and potential roadblocks suggests that the company's success may be heavily reliant on its ability to manage these external relationships.

Technical Analysis· Dec 10

$MCRB has been consolidating around $0.93-$0.94, with a potential breakout above $0.95.
The RSI is being pulled down, which could be a sign of a potential next leg up for $MCRB.
A third breakthrough of VWAP in one day would be a bullish sign, and the stock has already shown signs of a cup and handle pattern.

Generated by AI

Community

Of the messages about MCRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	41.67%	54.1%	63.97%	83.68%
Newcomers	58.33%	45.9%	36.03%	16.32%

Regulars· Jul 17

$MCRB is being mentioned alongside IOVA, suggesting a potential partnership or collaboration in the oncology space.
There is speculation about a potential oncology partnership involving MCRB, with one user expressing their belief in its potential.
MCRB is being used as a reference point in a discussion about time and market trends, with one user stating "I got nothing but time."

Newcomers· Jun 5

Many newcomers are focused on the company's cash runway, which has been extended to Q1 2027 due to recent transactions and reduced facility costs.
Some are optimistic about the company's balance sheet repairs and cash management, with a positive bias on the stock.
Others are concerned about the company's reliance on partnerships or additional capital raises for operations beyond Q1 2027.

Generated by AI

Seres Therapeutics

Social

Aug 14

Bullish· Jul 14

Bearish· Feb 12

Earnings· May 9

Analysts· Jul 23

Announcements· Jul 17

Macro· Feb 16

Technical Analysis· Dec 10

Regulars· Jul 17

Newcomers· Jun 5

Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Seres Therapeutics director Eric Shaff sells $1,196 in shares

Seres Therapeutics Files $300 Million Mixed Shelf

Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates

Seres Therapeutics: Q2 Earnings Snapshot

Also Discussed

Seres Therapeutics Inc.

Company Information

Location

Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Seres Therapeutics director Eric Shaff sells $1,196 in shares

Seres Therapeutics Files $300 Million Mixed Shelf

Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates

Seres Therapeutics: Q2 Earnings Snapshot

Also Discussed

Social

Aug 14

Bullish· Jul 14

Bearish· Feb 12

Earnings· May 9

Analysts· Jul 23

Announcements· Jul 17

Macro· Feb 16

Technical Analysis· Dec 10

Regulars· Jul 17

Newcomers· Jun 5